Sientra (SIEN) Upgraded to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Sientra (NASDAQ:SIEN) from a sell rating to a hold rating in a report issued on Saturday morning.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
SIEN has been the topic of a number of other research reports. Craig Hallum assumed coverage on Sientra in a research report on Monday, June 4th. They issued a buy rating and a $23.00 price objective on the stock. BidaskClub upgraded Sientra from a buy rating to a strong-buy rating in a research report on Wednesday, August 15th. Canaccord Genuity increased their price objective on Sientra from $19.00 to $25.00 and gave the stock a buy rating in a research report on Wednesday, August 8th. Stephens reiterated a buy rating and issued a $30.00 price objective on shares of Sientra in a research report on Thursday, August 9th. Finally, Stifel Nicolaus increased their price objective on Sientra from $21.00 to $25.00 and gave the stock a buy rating in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Sientra presently has a consensus rating of Buy and a consensus target price of $22.50.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.04). Sientra had a negative return on equity of 151.47% and a negative net margin of 131.16%. The business had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $15.30 million. analysts anticipate that Sientra will post -2.93 earnings per share for the current year.
In other Sientra news, CEO Jeffrey M. Nugent sold 1,852 shares of the firm’s stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $24.90, for a total transaction of $46,114.80. Following the sale, the chief executive officer now owns 297,999 shares in the company, valued at $7,420,175.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 31.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Sientra by 16.2% during the second quarter. Bank of America Corp DE now owns 26,638 shares of the medical instruments supplier’s stock valued at $519,000 after purchasing an additional 3,718 shares in the last quarter. Rhumbline Advisers raised its position in Sientra by 55.6% during the second quarter. Rhumbline Advisers now owns 21,621 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 7,725 shares in the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Sientra during the second quarter valued at about $160,000. BlackRock Inc. raised its position in Sientra by 1.2% during the first quarter. BlackRock Inc. now owns 767,308 shares of the medical instruments supplier’s stock valued at $7,411,000 after purchasing an additional 8,796 shares in the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in Sientra during the second quarter valued at about $210,000. Institutional investors and hedge funds own 89.21% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: Stock Symbols Definition, Examples, Lookup
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.